Oculis Holding AG announced on August 1, 2025, that it has amended its loan facility with funds and accounts managed by BlackRock, significantly increasing its borrowing capacity. The Amended Loan Agreement replaces a prior agreement from May 29, 2024, and now provides CHF 75.0 million in borrowing capacity, with the potential to increase to up to CHF 100.0 million.
The upsized loan comprises three tranches of CHF 25.0 million each, along with an additional loan of up to CHF 25.0 million that may be made available on mutually agreed terms. No amounts were drawn at the time of signing, indicating that this facility provides a flexible reserve rather than immediate funding.
This additional capital offers significant financial flexibility beyond Oculis’ current cash reserves, which are projected to provide a runway into early 2028. The funding supports upcoming key milestones across its core assets, including regulatory discussions for OCS-05, initiation of Phase 2/3 trials for OCS-02 and OCS-05, and the anticipated topline results for OCS-01 Phase 3 DIAMOND trials in Q2 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.